These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8529281)

  • 41. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Ando J; Matsui J; Suzuki K; Ikeda T; Inoue Y; Adachi K
    Br J Cancer; 1996 Sep; 74(5):704-10. PubMed ID: 8795571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency.
    Hata Y; Sandler A; Loehrer PJ; Sledge GW; Weber G
    Oncol Res; 1994; 6(1):19-24. PubMed ID: 7919548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.
    Zoli W; Flamigni A; Frassineti GL; Bajorko P; De Paola F; Milandri C; Amadori D; Gasperi-Campani A
    Breast Cancer Res Treat; 1995 Apr; 34(1):63-9. PubMed ID: 7749161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
    Magnetto S; Boissier S; Delmas PD; Clezardin P
    Int J Cancer; 1999 Oct; 83(2):263-9. PubMed ID: 10471537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
    Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
    Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
    Pinto AC; Moreira JN; Simões S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is there a place for "dose-dense" weekly schedules of the taxoids?
    Löffler TM
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):32-4. PubMed ID: 9865710
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
    Aapro MS
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines.
    Perez EA; Buckwalter CA
    Cancer Chemother Pharmacol; 1998; 41(6):448-52. PubMed ID: 9554587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
    Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y; Furukawa Y
    Jpn J Cancer Res; 2001 Jan; 92(1):74-82. PubMed ID: 11173547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Mori K; Suzuki K; Adachi KI
    Cancer Chemother Pharmacol; 1998; 42(2):91-8. PubMed ID: 9654107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Taxotere and methylnitrosourea: experimental appraisal of combination chemotherapy].
    Ostrovskaia LA; Korman DB; Bliukhterova NV; Fomina MM; Rykova VA
    Vopr Onkol; 1999; 45(4):429-33. PubMed ID: 10532105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Paclitaxel-based combination chemotherapy for breast cancer.
    Hortobagyi GN
    Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):29-37. PubMed ID: 9110340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.